{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:37:33Z","timestamp":1791805053527,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CAR-T cell therapy targeting CD19 demonstrated strong activity against advanced B cell leukemia, however shows less efficacy against lymphoma with nodal dissemination. To target both B cell Non-Hodgkin\u2019s lymphoma (B-NHLs) and follicular T helper (Tfh) cells in the tumor microenvironment (TME), we apply here a chimeric antigen receptor (CAR) that recognizes human CXCR5 with high avidity. CXCR5, physiologically expressed on mature B and Tfh cells, is also highly expressed on nodal B-NHLs. Anti-CXCR5 CAR-T cells eradicate B-NHL cells and lymphoma-supportive Tfh cells more potently than CD19 CAR-T cells in vitro, and they efficiently inhibit lymphoma growth in a murine xenograft model. Administration of anti-murine CXCR5 CAR-T cells in syngeneic mice specifically depletes endogenous and malignant B and Tfh cells without unexpected on-target\/off-tumor effects. Collectively, anti-CXCR5 CAR-T cells provide a promising treatment strategy for nodal B-NHLs through the simultaneous elimination of lymphoma B cells and Tfh cells of the tumor-supporting TME.<\/jats:p>","DOI":"10.1038\/s41467-020-20488-3","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T11:25:44Z","timestamp":1610364344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin\u2019s lymphoma and tumor-supportive follicular T helper cells"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-2520","authenticated-orcid":false,"given":"Mario","family":"Bunse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Pfeilschifter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bluhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zschummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-3216","authenticated-orcid":false,"given":"Jara J.","family":"Joedicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Wirges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5726-3958","authenticated-orcid":false,"given":"Helen","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Chmielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Uckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-3240","authenticated-orcid":false,"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-1950","authenticated-orcid":false,"given":"Armin","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-4893","authenticated-orcid":false,"given":"Uta E.","family":"H\u00f6pken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"20488_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","volume":"24","author":"JA Burger","year":"2014","unstructured":"Burger, J. A. & Gribben, J. G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol. 24, 71\u201381 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"20488_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00109-012-0906-z","volume":"90","author":"UE Hopken","year":"2012","unstructured":"Hopken, U. E. & Rehm, A. Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs. J. Mol. Med. 90, 1237\u20131245 (2012).","journal-title":"J. Mol. Med."},{"key":"20488_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"20488_CR4","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u20134190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"20488_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.23524","volume":"88","author":"SJ Nagle","year":"2013","unstructured":"Nagle, S. J. et al. Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am. J. Hematol. 88, 890\u2013894 (2013).","journal-title":"Am. J. Hematol."},{"key":"20488_CR6","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","volume":"3","author":"N Epperla","year":"2019","unstructured":"Epperla, N. et al. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 3, 1661\u20131669 (2019).","journal-title":"Blood Adv."},{"key":"20488_CR7","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"20488_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell Therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"20488_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"20488_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"20488_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1126\/scitranslmed.aaa3643","volume":"7","author":"CH June","year":"2015","unstructured":"June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7, 280\u2013287 (2015).","journal-title":"Sci. Transl. Med."},{"key":"20488_CR12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"20488_CR13","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"20488_CR14","first-page":"375","volume":"16","author":"PD Lulla","year":"2018","unstructured":"Lulla, P. D., Hill, L. C., Ramos, C. A. & Heslop, H. E. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin. Adv. Hematol. Oncol. 16, 375\u2013386 (2018).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"20488_CR15","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther.: J. Am. Soc. Gene Ther. 25, 2245\u20132253 (2017).","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"20488_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"20488_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"20488_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.trecan.2019.05.001","volume":"5","author":"UE Hopken","year":"2019","unstructured":"Hopken, U. E. & Rehm, A. Targeting the tumor microenvironment of leukemia and lymphoma. Trends Cancer 5, 351\u2013364 (2019).","journal-title":"Trends Cancer"},{"key":"20488_CR19","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"20488_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0092-8674(00)81798-5","volume":"87","author":"R Forster","year":"1996","unstructured":"Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037\u20131047 (1996).","journal-title":"Cell"},{"key":"20488_CR21","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1084\/jem.192.11.1545","volume":"192","author":"D Breitfeld","year":"2000","unstructured":"Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545\u20131552 (2000).","journal-title":"J. Exp. Med."},{"key":"20488_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1034\/j.1600-065X.2003.00073.x","volume":"195","author":"G Muller","year":"2003","unstructured":"Muller, G., Hopken, U. E. & Lipp, M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol. Rev. 195, 117\u2013135 (2003).","journal-title":"Immunol. Rev."},{"key":"20488_CR23","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ijc.24652","volume":"125","author":"A Rehm","year":"2009","unstructured":"Rehm, A. et al. Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int. J. Cancer 125, 2367\u20132374 (2009).","journal-title":"Int. J. Cancer"},{"key":"20488_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-015-0004-3","volume":"4","author":"S Middle","year":"2015","unstructured":"Middle, S. et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin\u2019s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp. Hematol. Oncol. 4, 10 (2015).","journal-title":"Exp. Hematol. Oncol."},{"key":"20488_CR25","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","volume":"110","author":"A Burkle","year":"2007","unstructured":"Burkle, A. et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110, 3316\u20133325 (2007).","journal-title":"Blood"},{"key":"20488_CR26","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/ijc.28893","volume":"135","author":"H Panjideh","year":"2014","unstructured":"Panjideh, H. et al. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model. Int. J. Cancer 135, 2623\u20132632 (2014).","journal-title":"Int. J. Cancer"},{"key":"20488_CR27","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1158\/2159-8290.CD-14-0096","volume":"4","author":"K Heinig","year":"2014","unstructured":"Heinig, K. et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov. 4, 1448\u20131465 (2014).","journal-title":"Cancer Discov."},{"key":"20488_CR28","doi-asserted-by":"publisher","first-page":"420747","DOI":"10.1155\/2008\/420747","volume":"2008","author":"T Hruz","year":"2008","unstructured":"Hruz, T. et al. Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv. Bioinforma. 2008, 420747 (2008).","journal-title":"Adv. Bioinforma."},{"key":"20488_CR29","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1006\/bbrc.1993.2421","volume":"196","author":"R Forster","year":"1993","unstructured":"Forster, R., Emrich, T., Voss, C. & Lipp, M. A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA. Biochem. Biophys. Res. Commun. 196, 1496\u20131503 (1993).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"20488_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood.V84.3.830.bloodjournal843830","volume":"84","author":"R Forster","year":"1994","unstructured":"Forster, R., Emrich, T., Kremmer, E. & Lipp, M. Expression of the G-protein\u2013coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood 84, 830\u2013840 (1994).","journal-title":"Blood"},{"key":"20488_CR31","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","volume":"26","author":"J Bluhm","year":"2018","unstructured":"Bluhm, J. et al. CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin\u2019s lymphoma and multiple myeloma. Mol. Ther. 26, 1906\u20131920 (2018).","journal-title":"Mol. Ther."},{"key":"20488_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"20488_CR33","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp, S. et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31, 1743\u20131751 (2017).","journal-title":"Leukemia"},{"key":"20488_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","volume":"3","author":"A Kunkele","year":"2015","unstructured":"Kunkele, A. et al. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol. Res. 3, 368\u2013379 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"20488_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 712 (2016).","journal-title":"Immunity"},{"key":"20488_CR36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","volume":"2017","author":"K Tarte","year":"2017","unstructured":"Tarte, K. Role of the microenvironment across histological subtypes of NHL. Hematol. Am. Soc. Hematol. Educ. Program 2017, 610\u2013617 (2017).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"20488_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.12401","volume":"162","author":"MJ Ahearne","year":"2013","unstructured":"Ahearne, M. J. et al. Enhancement of CD154\/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. Br. J. Haematol. 162, 360\u2013370 (2013).","journal-title":"Br. J. Haematol."},{"key":"20488_CR38","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/leu.2011.301","volume":"26","author":"P Ame-Thomas","year":"2012","unstructured":"Ame-Thomas, P. et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26, 1053\u20131063 (2012).","journal-title":"Leukemia"},{"key":"20488_CR39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.leu.2402107","volume":"15","author":"J Durig","year":"2001","unstructured":"Durig, J., Schmucker, U. & Duhrsen, U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 15, 752\u2013756 (2001).","journal-title":"Leukemia"},{"key":"20488_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1182\/blood-2003-09-3103","volume":"104","author":"L Trentin","year":"2004","unstructured":"Trentin, L. et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104, 502\u2013508 (2004).","journal-title":"Blood"},{"key":"20488_CR41","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1080\/10428190410001723449","volume":"45","author":"S Wong","year":"2004","unstructured":"Wong, S. & Fulcher, D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk. lymphoma 45, 2491\u20132496 (2004).","journal-title":"Leuk. lymphoma"},{"key":"20488_CR42","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1189\/jlb.1203652","volume":"76","author":"S Lopez-Giral","year":"2004","unstructured":"Lopez-Giral, S. et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J. Leukoc. Biol. 76, 462\u2013471 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"20488_CR43","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova, A. V., Tamayo, A. T., Ford, R. J. & Burger, J. A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604\u20134613 (2009).","journal-title":"Blood"},{"key":"20488_CR44","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","volume":"122","author":"MF Pascutti","year":"2013","unstructured":"Pascutti, M. F. et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 122, 3010\u20133019 (2013).","journal-title":"Blood"},{"key":"20488_CR45","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/leu.2010.223","volume":"24","author":"C Pangault","year":"2010","unstructured":"Pangault, C. et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24, 2080\u20132089 (2010).","journal-title":"Leukemia"},{"key":"20488_CR46","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/blood-2015-02-625152","volume":"125","author":"P Ame-Thomas","year":"2015","unstructured":"Ame-Thomas, P. et al. CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. Blood 125, 2381\u20132385 (2015).","journal-title":"Blood"},{"key":"20488_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.25032","volume":"62","author":"N Simpson","year":"2010","unstructured":"Simpson, N. et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheumatism 62, 234\u2013244 (2010).","journal-title":"Arthritis Rheumatism"},{"key":"20488_CR48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","volume":"34","author":"R Morita","year":"2011","unstructured":"Morita, R. et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34, 108\u2013121 (2011).","journal-title":"Immunity"},{"key":"20488_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.yexcr.2016.11.017","volume":"350","author":"Z Cha","year":"2017","unstructured":"Cha, Z. et al. Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway. Exp. Cell Res. 350, 154\u2013160 (2017).","journal-title":"Exp. Cell Res."},{"key":"20488_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/bjh.12941","volume":"166","author":"MJ Ahearne","year":"2014","unstructured":"Ahearne, M. J., Allchin, R. L., Fox, C. P. & Wagner, S. D. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br. J. Haematol. 166, 326\u2013335 (2014).","journal-title":"Br. J. Haematol."},{"key":"20488_CR51","doi-asserted-by":"crossref","unstructured":"Chu, F. et al. CXCR5(+)CD8(+) T cells are a distinct functional subset with an antitumor activity. Leukemia 33, 2640\u20132653 (2019).","DOI":"10.1038\/s41375-019-0464-2"},{"key":"20488_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1172\/JCI81950","volume":"126","author":"BC Jiang","year":"2016","unstructured":"Jiang, B. C. et al. CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J. Clin. Investig. 126, 745\u2013761 (2016).","journal-title":"J. Clin. Investig."},{"key":"20488_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nature17623","volume":"532","author":"MA Anderson","year":"2016","unstructured":"Anderson, M. A. et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195\u2013200 (2016).","journal-title":"Nature"},{"key":"20488_CR54","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1084\/jem.20182375","volume":"216","author":"M Cazaux","year":"2019","unstructured":"Cazaux, M. et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J. Exp. Med. 216, 1038\u20131049 (2019).","journal-title":"J. Exp. Med."},{"key":"20488_CR55","doi-asserted-by":"crossref","unstructured":"Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).","DOI":"10.1126\/scitranslmed.aav1648"},{"key":"20488_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"20488_CR57","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheumatism 54, 2793\u20132806 (2006).","journal-title":"Arthritis Rheumatism"},{"key":"20488_CR58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1056\/NEJMe1614717","volume":"376","author":"PA Calabresi","year":"2017","unstructured":"Calabresi, P. A. B-cell depletion - a frontier in monoclonal antibodies for multiple sclerosis. N. Engl. J. Med. 376, 280\u2013282 (2017).","journal-title":"N. Engl. J. Med."},{"key":"20488_CR59","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","volume":"17","author":"A Hombach","year":"2010","unstructured":"Hombach, A., Hombach, A. A. & Abken, H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u2018spacer\u2019 domain in the extracellular moiety of chimeric antigen receptors avoids \u2018off-target\u2019 activation and unintended initiation of an innate immune response. Gene Ther. 17, 1206\u20131213 (2010).","journal-title":"Gene Ther."},{"key":"20488_CR60","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","volume":"128","author":"E Faitschuk","year":"2016","unstructured":"Faitschuk, E., Hombach, A. A., Frenzel, L. P., Wendtner, C. M. & Abken, H. Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells. Blood 128, 1711\u20131722 (2016).","journal-title":"Blood"},{"key":"20488_CR61","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/104303403322167993","volume":"14","author":"B Engels","year":"2003","unstructured":"Engels, B. et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14, 1155\u20131168 (2003).","journal-title":"Hum. Gene Ther."},{"key":"20488_CR62","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"20488_CR63","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","volume":"33","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei, P., Izsvak, Z., Narayanavari, S. A., Singh, H. & Ivics, Z. Gene therapy with the sleeping beauty transposon system. Trends Genet. 33, 852\u2013870 (2017).","journal-title":"Trends Genet."},{"key":"20488_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1389-1723(00)80103-6","volume":"90","author":"S Morita","year":"2000","unstructured":"Morita, S., Umakoshi, H. & Kuboi, R. Dielectric response of cells and liposomes and its utilization for evaluation of cell membrane-protein interaction. J. Biosci. Bioeng. 90, 157\u2013162 (2000).","journal-title":"J. Biosci. Bioeng."},{"key":"20488_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nature03954","volume":"437","author":"G Willimsky","year":"2005","unstructured":"Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141\u2013146 (2005).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20488-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20488-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20488-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:10:55Z","timestamp":1669975855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20488-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["20488"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-20488-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.E.H., A.R. J.B., and W.U. acknowledge filed patent application WO 2019\/038368 A1 \u201cChimeric antigen receptor and CAR-T cells that bind CXCR5\u201d related to the work disclosed in this paper. All authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}